Novartis

Summary- Leading the charge for Narasimhan’s blockbuster launch list is cholesterol therapy Leqvio, which awaits an FDA decision on Jan. 1. Others…

Novartis says that the U.S. and European regulators have accepted its marketing applications for CAR-T cell therapy Kymriah (Tisagenlecleucel) as third-line therapy…